Related Experiment Video
Updated: Mar 13, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
8.2K
Relationship between oxysterols and mild cognitive impairment in the elderly: a case-control study
Quanri Liu1, Yu An1, Huanling Yu1
1School of Public Health, Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, No.10 Xitoutiao, You An Men Wai, Beijing, 100069, Fengtai District, China.
Lipids in Health and Disease
|October 12, 2016
Summary
High levels of 27-hydroxycholesterol (27-OHC) in the blood are linked to mild cognitive impairment (MCI). This finding suggests 27-OHC may play a role in MCI development.
Area of Science:
- Biochemistry
- Neuroscience
- Gerontology
Background:
- Mild cognitive impairment (MCI) is a precursor to dementia.
- Oxysterols, cholesterol metabolites, are implicated in neurodegenerative diseases.
Purpose of the Study:
- To investigate the association between plasma oxysterol levels and MCI.
- To determine if specific oxysterols are biomarkers for MCI.
Main Methods:
- A matched case-control study comparing 70 MCI patients and 140 controls.
- Plasma oxysterol levels (27-OHC, 24S-OHC, 7α-OHC, 7β-OHC) measured by HPLC-MS.
- Logistic regression analysis used to calculate odds ratios (OR) for MCI risk.
Main Results:
- Plasma 27-hydroxycholesterol (27-OHC) levels were significantly elevated in MCI patients compared to controls.
- High 27-OHC levels were strongly associated with MCI, with an OR of 2.86 after multivariate adjustment.
- No significant associations were found for other measured oxysterols.
Conclusions:
- Increased plasma 27-OHC levels are significantly associated with mild cognitive impairment.
- Elevated 27-OHC may be a risk factor or early biomarker for MCI development.
- Further research is warranted to elucidate the role of 27-OHC in cognitive decline.
Keywords:
27–hydroxycholesterolAlzheimer’s diseaseAβ1-40Aβ1-42Mild cognitive impairmentMoCAOxysterolsMore Related Videos
Related Concept Videos
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
291
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
291
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
308
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
308
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:15Drug Dosing: Geriatric Patients
339
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
339
01:26Atherosclerosis III: Management
556
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
556